At 19.54 15/09/98 +0100, you wrote:
>I wish to know all there about NNT. Pointers in the right direction will be
>appreciated.
>--Sudheer Manthri
Further to Dave Sackett's and Andrew Booth's excellent references, here is
others papers to "know all there about NNT"
1. These studies show that physicians, policymakers and patients are
influenced from the methods of presenting clinical trials.
- Bobbio M, Demichelis B,Giustetto G. Completeness of reporting trial
result: effect on physicians' willingness to prescribe. Lancet
1994;343:1209-11.
- Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the methods of
reporting trial result alter perception of therapeutic effectiveness? Ann
Intern Med 1992;117:916-21.
- Forrow L, Taylor W, Arnold R. Absolutely relative: how research results
are summarised can affect treatment decision. Am J Med 1992;92:121-4.
- Bucher HC, Weinbacher M, Gyr K. Influence of method of reporting study
results on decision of physicians to prescribe drugs to lower cholesterol
concentration. BMJ 1994;309:761-4.
- Fahey T, Griffiths S, Peters TJ. Evidence based purchaising :
understanding results of clinical trials and systematic reviews. BMJ
1995;311:1056-60
- Hux JE, Naylor CD. Communicating the benefits of chronic preventive
therapy: does the format of efficacy data determine patients' acceptance of
treatments? Med Decis Making 1995;15:152-7.
- John-Arne Skolbekken. Communicating the risk reduction achieved by
cholesterol reducing drugs. BMJ 1998;316:1956-1958
<http://www.bmj.com/cgi/content/full/316/7149/1956>
2. Some "hard" papers about NNT:
- Riegelman R, Schroth WS. Adjusting the number needed to treat:
incorporating adjustments for the utility and timing of benefits and harms.
Med Decis Making 1993;13:247-52.
- Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure':
number-needed-to-treat- related concepts for assessing treatment efficacy
in the presence of treatment-induced adverse events. Int J Epidemiol
1996;25:704-12.
- Willan AR, O'Brien BJ, Cook DJ. Benefit-risk ratios in the assessment of
the clinical evidence of a new therapy. Control Clin Trials 1997;18:121-30.
3. Some application of NNT (!):
- Miller DB. Secondary prevention for ischemic heart disease. Relative
numbers needed to treat with different therapies. Arch Intern Med
1997;157:2045-52.
- Rembold CM. Number-needed-to-treat analysis of the prevention of
myocardial infarction and death by antidyslipidemic therapy [see comments].
J Fam Pract 1996;42:577-86.
Bests
Nino
P.S. If you have other specific requests, write me
------------------------------------------------------------------
Gruppo Italiano per la Medicina Basata sulle Evidenze
------------------------------------------------------------------
Antonino Cartabellotta, MD Phone:+39 091 407153
Head of GIMBE Fax: +39 091 407153
Passaggio L. da Vinci, 16 [log in to unmask]
90145 - Palermo (Italy) http://www.gimbe.org
------------------------------------------------------------------
G I M B E
------------------------------------------------------------------
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
